GLP-1 Weight Loss at 4 Weeks: Month One Results

Quick Answer

After 4 weeks on GLP-1, most patients have lost 3–8 lbs. At week 4, semaglutide patients are completing the starting dose (0.25 mg) and transitioning to 0.5 mg — so the full effect is still building. By month 1, about 80% of patients report noticeable appetite reduction, and most have adjusted to the initial side effects.

What Typically Happens at Week 4

Week 4 is the transition point for most GLP-1 titration schedules. Patients completing their first 4 weeks at the lowest dose are about to move to the next level:

Semaglutide: 0.25 mg → 0.5 mg
Tirzepatide: 2.5 mg → 5 mg

This transition typically brings a noticeable increase in appetite suppression — and often a temporary return of mild nausea as the body adjusts to the higher dose.

Typical Weight Loss at 4 Weeks

Based on clinical trial data from the STEP program:

Week 4 average on semaglutide: approximately 4–6 lbs lost from starting weight
Week 4 average on tirzepatide: approximately 5–7 lbs lost

These are averages from large trials. Individual results range widely:

Some patients have lost 10–12 lbs by week 4 (typically those with large starting appetite reduction and high initial caloric intake)
Some patients have lost 1–3 lbs (typically those with persistent nausea reducing food intake but also water intake, or those still at modest dose effect)

At 4 weeks, you haven't yet experienced anywhere near the medication's full effect. The best results come between months 3–9.

Body Changes Beyond the Scale at 4 Weeks

What's measurable at 4 weeks that goes beyond weight:

Appetite: Most patients (roughly 80%) describe meaningful appetite reduction by week 4. The change is typically described as "I just don't think about food as much" or "I feel full after much smaller portions."

Fasting blood glucose: In patients with diabetes or prediabetes, GLP-1 medications show significant fasting glucose improvement within the first 4 weeks — sometimes before meaningful weight loss occurs.

Blood pressure: A modest early drop in blood pressure (2–4 mmHg systolic) can appear within the first month in patients with hypertension.

Digestion rhythm: Most patients have established a new normal for gastric emptying by week 4 — meals move through the stomach more slowly, producing longer satiety periods.

What Affects Your 4-Week Result

Nausea severity: Patients who experience significant nausea often eat less than they otherwise would — which can actually produce faster early weight loss, but is uncomfortable. Patients who tolerate the starting dose well may eat less dramatically in month 1 but feel better.

Starting caloric intake: Patients who were eating very high caloric loads before starting GLP-1 tend to show larger early reductions in caloric intake and faster initial weight loss.

Exercise: Adding even light walking significantly increases the caloric deficit created by appetite reduction.

Processed food reduction: Many patients naturally gravitate away from ultra-processed, high-fat foods (which can worsen nausea) in the first month. This dietary shift amplifies early results.

How 4-Week Results Predict Long-Term Outcome

The correlation between 4-week results and final weight loss is moderate but imperfect. Some patients who lose little in month 1 go on to lose substantial weight at higher doses. However, early response at week 4 does provide some signal:

Losing 5%+ by week 12 is a strong predictor of good long-term response
Losing less than 2% by week 12 at adequate dose warrants discussion with your provider about response and whether medication adjustment is needed

Week 4 specifically is too early to draw conclusions. Week 12–16 at the maintenance dose is the appropriate time to evaluate response.

Start Your GLP-1 Treatment

Bottom Line

Week 4 on GLP-1 typically means 4–7 lbs lost and moving to the second dose level. It's not a dramatic visual transformation yet, but the biological machinery is running. Most patients describe meaningful appetite changes by this point, which is the most reliable early indicator of eventual success.